SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
October 10, 1997
________________________________________
THERMOTREX CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 1-10791 52-1711436
(State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification Number)
incorporation or
organization)
10455 Pacific Center Court
San Diego, California 92121-4339
(Address of principal executive offices) (Zip Code)
(619) 646-5300
(Registrant's telephone number
including area code)
PAGE
<PAGE>
Item 5. Other Events
------------
On October 10, 1997, ThermoTrex Corporation (the "Company")
issued a press release, attached hereto as Exhibit 99, to
announce its estimated earnings for the quarter ended September
27, 1997.
Item 7. Financial Statements, Pro Forma Financial Information
-----------------------------------------------------
and Exhibits
------------
(a) Financial Statements of Business Acquired: not
applicable.
(b) Pro Forma Financial Information: not applicable.
(c) Exhibits
99 Press Release of the Company, dated October 10,
1997
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized, on
this 10th day of October, 1997.
THERMOTREX CORPORATION
By: /s/ Melissa F. Riordan
------------------------
Melissa F. Riordan
Treasurer
AA972800034
PAGE
<PAGE>
EXHIBIT 99
----------
THERMOTREX ANNOUNCES FOURTH QUARTER
EARNINGS ESTIMATE
SAN DIEGO, Calif., October 10, 1997 -- ThermoTrex
Corporation (ASE-TKN) announced today that it expects earnings
for the quarter ended September 27, 1997, to be between $4.8
million and $5.3 million, or between $.25 and $.27 per share,
compared with earnings of $25.2 million, or $1.32 per share, for
the same quarter in 1996. Earnings for the quarter ended
September 27, 1997, reflect a $5.9 million gain from the private
placement of common stock by the company's Trex Communications
Corporation subsidiary and a $1.4 million write-off of technology
in development, incurred in connection with the company's
acquisition of Computer Communications Specialists, Inc. on July
18. Earnings for the quarter ended September 28, 1996, included
a gain of $25.6 million from the initial public offering and
concurrent rights offering by the Company's Trex Medical
Corporation subsidiary.
"We ended the fourth quarter of 1997 by completing a private
placement in our newest subsidiary, Trex Communications, which
provides a foothold in the fast-growing telecommunications
field," said Gary Weinstein, chairman and chief executive officer
of ThermoTrex. "We believe that the free-space laser
communication system this business is developing can address the
current need for increased bandwidth."
Thermo Trex Corporation manufactures general-purpose and
specialized X-ray equipment as well as minimally invasive
breast-biopsy systems. In addition, the company offers
personal-care products and laser-based hair-removal services.
ThermoTrex also conducts advanced technology R&D and is currently
developing a laser communication system, products for the medical
imaging and avionics markets, and is pursuing industrial
applications for its advanced materials technology. ThermoTrex
is a public subsidiary of Thermo Electron Corporation. More
information is available on the Internet at http://www.thermo.com
/subsid/tkn.html.
This press release contains forward-looking statements that
involve a number of risks and uncertainties. Important factors
that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth under
the caption "Forward-looking Statements" in Exhibit 13 to the
company's annual report on Form 10-K for the year ended September
28, 1996. These include uncertainties in market demand and
acceptance, government regulation and approvals, and intellectual
property rights and litigation; the impact of healthcare reform
programs and competitive products and pricing; and risks
associated with technology and product development and
commercialization, potential product liability, management of
growth, and dependence on significant OEM relationships.
